Skip to content
Clinical Trials – home

Vilniaus universiteto ligonine Santaros klinikos VšĮ

VerifiedinfoResponsive

Lithuania Santariskiu G. 2, Vilniaus M. Sav., 08406 Vilnius, Lithuania

  • 48 trials recruiting
  • Colitis ulcerative · Acute myeloid leukaemia · Crohn's disease
  • Adults and children

About Specializations

Vilniaus universiteto ligonine Santaros klinikos VšĮ in Vilnius, Lithuania specialises in clinical trials of conditions such as Colitis ulcerative, Acute myeloid leukaemia, Crohn's disease, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases and Stroke Prevention

At Vilniaus universiteto ligonine Santaros klinikos VšĮ, cardiovascular research is a major focus, with studies in acute coronary syndrome, atrial fibrillation, acute myocardial infarction, and broader atherosclerotic cardiovascular disease. These trials are designed to test new ways to prevent serious events, reduce clot-related complications, and improve long-term heart and vascular outcomes.

  • Testing new therapies to lower the risk of stroke, heart attack, and systemic embolism
  • Evaluating treatments for patients with atrial fibrillation and other high-risk cardiovascular conditions
  • Studying strategies for primary and secondary prevention of major cardiovascular events

This area also includes research on safer anticoagulation and improved cardiovascular protection for patients with elevated lipoprotein(a) and related risk factors.

Neurology, Epilepsy, and Multiple Sclerosis

The site is actively involved in neurological research covering refractory status epilepticus, focal seizures, epilepsy, and multiple sclerosis. These trials aim to improve symptom control, support long-term disease management, and assess the safety of new treatment approaches for complex nervous system disorders.

  • Evaluating new options for difficult-to-control seizures and emergency seizure care
  • Studying long-term treatment safety in relapsing and progressive multiple sclerosis
  • Assessing therapies intended to improve outcomes in epilepsy and other nervous system diseases

This research reflects a strong interest in both urgent neurological care and chronic disease control.

Rheumatology and Immune System Diseases

Immunology-focused trials at this hospital include rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, and idiopathic inflammatory myopathy. The research is centered on improving disease control, reducing inflammation, and evaluating the long-term safety and effectiveness of advanced therapies.

  • Testing treatments for active autoimmune and inflammatory joint disease
  • Studying therapies for systemic lupus erythematosus and related immune-mediated conditions
  • Assessing whether new medicines can better control symptoms and slow progression

These studies are important for patients with chronic immune-related illness who need more durable treatment options.

Gastroenterology and Inflammatory Bowel Disease

Research in digestive diseases includes Crohn's disease and ulcerative colitis, with a focus on treatments that may improve remission rates and maintain disease control over time. The studies are aimed at helping people with moderate to severe inflammatory bowel disease achieve better symptom relief and fewer flare-ups.

  • Evaluating therapies for active ulcerative colitis
  • Studying maintenance treatment strategies in Crohn's disease
  • Exploring new approaches to support long-term remission in digestive system disease

This area highlights ongoing efforts to improve both short-term response and sustained control of intestinal inflammation.

Oncology and Hematology

The oncology portfolio includes trials in acute myeloid leukemia, myelodysplastic syndrome, endometrial cancer, prostate cancer, and colorectal cancer. These studies are designed to evaluate new cancer therapies, understand treatment benefit, and support better outcomes for patients with advanced or recurrent disease.

  • Testing new treatment options for blood cancers such as AML and MDS
  • Studying therapies for advanced solid tumors, including endometrial and prostate cancer
  • Assessing whether investigational approaches can improve survival and disease control

This is one of the broadest research areas at the site, combining neoplasms and hematologic disease expertise.

Ophthalmology and Vision Research

Eye-related research at the site focuses on macular edema secondary to retinal vein occlusion. The main goal is to examine whether new treatment approaches can improve vision and help preserve eye health in people with retinal disease.

  • Evaluating treatments for reduced vision caused by retinal vein-related swelling
  • Studying ways to improve visual acuity and patient function
  • Assessing the safety and effectiveness of ophthalmic therapy

These studies support better care for patients with sight-threatening retinal conditions.

Respiratory and Vascular Research

The site also participates in studies of pulmonary arterial hypertension and related vascular conditions. This research focuses on whether new add-on treatments can slow disease progression and improve outcomes in patients with serious circulatory and breathing-related illness.

  • Testing therapies for pulmonary arterial hypertension in children and other affected groups
  • Investigating treatment effectiveness in diseases affecting blood vessels and cardiopulmonary function
  • Supporting better long-term management of progressive vascular disease

These trials reflect the site’s broader interest in conditions where circulation and organ function are closely linked.

Dermatology, Haematology, and Other Specialized Studies

Additional research areas include hidradenitis suppurativa, haemophilia A, and other immune- and blood-related disorders. The purpose of these trials is to test new therapies, improve disease control, and expand options for patients with chronic or difficult-to-treat conditions.

  • Studying new treatment approaches for inflammatory skin disease
  • Evaluating prevention strategies and long-term care in haemophilia A
  • Exploring therapies for conditions involving immune system processes and bleeding disorders

This mix of studies shows the site’s wide-ranging clinical trial activity across both common and highly specialized diseases.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Santariskiu G. 2, Vilniaus M. Sav.08406 VilniusLithuania
Recruiting now
48 trials
Conditions studied
94
Partner status
Verified

More sites in VilniusLithuania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

130 clinical trials

Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bronchiectasis

Recruiting
Investigational
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bi 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting
Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC
Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bi 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.